[1]张浩 王晶* 周琳 赵东峰 赵永见卫晓恩 王拥军 舒冰△.肾性骨病方对5/6肾切除术后小鼠骨丢失影响的作用机制研究[J].中国中医骨伤科杂志,2021,29(10):1-8.
　ZHANG Hao WANG Jing* ZHOU Lin ZHAO DongfengZHAO Yongjian WEIXiaoen WANG Yongjun SHU Bing.Study on the Mechanism of Shenxinggubing Decoction onBone Loss in Mice after 5/6 Nephrectomy[J].Chinese Journal of Traditional Medical Traumatology & Orthopedics,2021,29(10):1-8.
点击复制

肾性骨病方对5/6肾切除术后小鼠骨丢失影响的作用机制研究()
分享到：

《中国中医骨伤科杂志》[ISSN:1005-0205/CN:42-1340/R]

卷:
第29卷
期数:
2021年10期
页码:
1-8
栏目:
实验研究
出版日期:
2021-10-15

文章信息/Info

Title:
Study on the Mechanism of Shenxinggubing Decoction onBone Loss in Mice after 5/6 Nephrectomy
文章编号:
1005-0205(2021)10-0001-08
作者:
张浩1; 2 王晶1; 3; 4; 5* 周琳1; 2 赵东峰1; 3; 4 赵永见1; 3; 4卫晓恩 1; 2 王拥军1; 3; 4 舒冰1; 3; 4△
1上海中医药大学附属曙光医院(上海,200000)2上海中医药大学3上海中医药大学脊柱病研究所4教育部重点实验室(筋骨理论与治法)5上海市中医老年病研究所
Author(s):
ZHANG Hao1; 2 WANG Jing1; 3; 4; 5* ZHOU Lin1; 2 ZHAO Dongfeng1; 3; 4ZHAO Yongjian1; 3; 4 WEIXiaoen1; 2 WANG Yongjun1; 3; 4 SHU Bing1; 3; 4△
关键词:
肾性骨病;  5/6肾切除;  肾性骨病方;  肾功能;  骨丢失
Keywords:
renal osteodystrophy;  Shenxinggubing decoction;  5/6 nephrectomy;  renal function;  bone loss
分类号:
R-33
文献标志码:
A
摘要:
目的:比较肾性骨病方对不同阶段5/6 肾切除小鼠骨丢失的保护作用机制。方法:3个月龄C57BL/6J小鼠150只,建立慢性肾衰小鼠模型,术后随机分为假手术组、模型组、罗盖全组、肾性骨病方组,分别在术后1周和4周时给予肾性骨病方以及罗盖全灌胃。各组给药8周后,取小鼠 L5椎体、血清和肾脏组织,分别检测血清肌酐(CREA)、尿素氮(BUN),以评估肾脏功能; L5椎体进行阿尔辛兰/橙黄G染色、Micro-CT扫描加重建、免疫组化检测评估骨质情况。结果:和假手术组相比,模型组小鼠血清肌酐、血清尿素氮明显升高; 和模型组相比,早期应用肾性骨病方干预后小鼠腰椎骨丢失情况较晚期各组得到明显改善; 早期组小鼠L5腰椎Osterix表达明显升高而Cathepsin K表达明显降低; 与之一致,TRAP染色显示早期应用肾性骨病方可以显著抑制破骨细胞活性,降低破骨细胞数量。结论:早期应用肾性骨病方可以有效改善5/6肾切除小鼠肾功能,缓解骨丢失。
Abstract:
Objective:To compare the protective mechanism of shenxinggubing decoction on bone loss in 5/6 nephrectomized mice at different stages. Methods:A total of 150 male C57BL/6J mice of 3-month-old were selected to establish the mouse model of chronic renal failure and randomly divided into sham group, model group, Shenxinggubing(SXGBF)group and Rocaltrol group. Shenxinggubing decoction and Rocaltrol were orally administrated at postoperative 1 week stage and 4 weeks stage respectively. After 8 weeks administration, L5 vertebrae, serum and kidney tissue of mice were taken to detect serum creatinine(CREA)and blood urea nitrogen(BUN). Arsine blue/orange G, Micro-CT scanning and reconstruction, and immunohistochemistry was used to evaluate bone condition in lumbar 5 vertebrae(L5). Results:Compared with sham group, serum CREA and BUN were significantly increased in model group. Compared with the model group, the bone loss of mics lumbar vertebra in the groups with early intervention of SXGBF decoction were significant improved than the late groups. In the early group, the expression of osterix in L5 lumbar vertebra was significantly increased and Cathepsin K was significantly decreased. In accordance with this, TRAP staining showed that early application of kidney osteopathy prescription could significantly inhibit the activity of osteoclasts and reduce the number of osteoclasts. Conclusion:The early application of SXGBF decoction effectively relieve renal insufficiency and bone loss in 5/6 nephrectomized mice.

参考文献/References:

[1] ENE-IORDACHE B, PERICO N, BIKBOV B,et al,Chronic kidney disease and cardiovascular riskin six regions of the world(ISN-KDDC):a cross-sectional study[J].Lancet Glob Health,2016,4(5):e307-e319.
[2] PAZIANAS M, MILLER P D.The CKD-MBD syndrome:hysteresis in PTH involvement and PTH administration for its management[J].Journal of Bone and Mineral Research,2020,35(12):2313-2317.
[3] MOE S M,NICKOLAS T L.Chapter 60-Renal osteodystrophy and chronic kidney disease-mineral bone disorder[M]//Principles of Bone Biology.4th Edition.Amsterdam:Elsevier,2020:1463-1487.
[4] RROJI M, FIGUREK A, SPASOVSKI G.Should we consider the cardiovascular system while evaluating CKD-MBD?[J].Toxins,2020,12(3):140.
[5] COVIC A,VERVLOET M,MASSY Z A.et al.Bone and mineral disorders in chronic kidney disease:implications for cardiovascular health and ageing in the general population[J].Lancet Diabetes Endocrinol,2018,6(4):319-331.
[6] 钱学民.“肾藏精,主骨生髓”与肾性骨营养不良辨析[J].实用中医内科杂志,2010,24(11):72-73.
[7] PHAM C V, PHAM T T, LAI T T,et al.Icariin reduces bone loss in a Rankl-inducedtransgenic medaka(Oryzias latipes)model for osteoporosis[J].Journal of Fish Biology,2021,98(4):1039-1048.
[8] ZHOU L, POON C C W, WONG K Y,et al.Icariin ameliorates estrogen-deficiency induced bone loss by enhancing IGF-I signaling via its crosstalk with non-genomic ERα signaling[J].Phytomedicine,2021,82:153413.
[9] ZHANG T,HAN W,ZHAO K,et al.Psoralen accelerates bone fracture healing by activating both osteoclasts and osteoblasts(vol 33,pg 5399,2019)[J].Faseb Journal,2020,34(9):13069.
[10] LI H,MENG D,ZHANG X,et al.Effect of psoralen on the expression of PPARγ,osteocalcin,and trabecular bone area in rabbits with steroid-induced avascular necrosis of the femoral head[J].J Orthop Surg Res,2019,14(1):11.
[11] LI L,CHEN B,ZHU R,et al.Fructus ligustri lucidi preserves bone quality through the regulation of gut microbiota diversity,oxidative stress,TMAO and Sirt6 levels in aging mice[J].Aging(Albany N Y),2019,11(21):9348.
[12] GUO Y,WANG L,MA R,et al.Effects of water extract from Fructus Ligustri Lucidi on bone structure and metabolism in ovariectomized rats[J].Chin Tradit Herb Drugs,2016,47:1155-1162.
[13] YAO X,JING X,GUO J,et al.Icariin protects bone marrow mesenchymal stem cells against iron overload induced dysfunction through mitochondrial fusion and fission,PI3K/AKT/mTOR and MAPK pathways[J].Frontiers in Pharmacology,2019,10:163.
[14] LI X,XUE C,WANG L,et al,Osteoprotective effects of osthole in a mouse model of 5/6 nephrectomy through inhibiting osteoclast formation[J].Mol Med Rep,2016,14(4):3769-3776.
[15] KANG E Y,KIM H K,JUNG J Y,et al.Combined extract of leonurus japonicus Houtt,Eclipta prostrata L.,and pueraria lobata ohwi improved hot flashes and depression in an ovariectomized rat model of menopause[J].Foods,2021,10(1):180.
[16] HUANG X,WANG X,ZHANG Y,et al.Absorption and utilisation of epimedin C and icariin from Epimedii herba,and the regulatory mechanism via the BMP2/Runx2 signalling pathway[J].Biomedicine & Pharmacotherapy,2019,118:109345.
[17] SUNJ,WANG Z,AN W.Protection of icariin against hydrogen peroxide-induced MC3T3-E1 cell oxidative damage[J].Orthopaedic Surgery,2021,13(2):632-640.
[18] LIN J,ZHU J,WANG Y,et al.Chinese single herbs and active ingredients for postmenopausal osteoporosis:From preclinical evidence to action mechanism[J].Bioscience Trends,2017,11(5):496-506.
[19] Kidney Disease:Improving Global Outcomes(KDIGO)CKD-MBD Work Group.KDIGO 2017 clinical practice guideline update for the diagnosis,evaluation,prevention,and treatment of chronic kidney disease-mineral and bone disorder(CKD-MBD)[J].Kidney Int Suppl,2017,7(1):1-59.
[20] LUO W,JIANG Y,YI Z,et al.1ɑ,25-dihydroxyvitamin D3 promotes osteogenesis by down-regulating FGF23 in diabetic mice[J].Journal of Cellular and Molecular Medicine,2021,25(8):4148-4156.
[21] NOAUTHORS LISTED.Chapter 4.1:Treatment of CKD-MBD targeted at lowering high serum phosphorus and maintaining serum calcium[J].Kidney Int,2009,76113:S50-S99.
[22] Kidney Disease:Improving Global Outcomes(KDIGO)CKD-MBD Work Group.KDIGO 2017 clinical practice guideline update for the diagnosis,evaluation,prevention,and treatment of Chronic Kidney Disease-Mineral and Bone Disorder(CKD-MBD)[J].Kidney Int,2017(2):S1-S55.
[23] WAQAS M, WANG Y, LI A,et al.Osthole:a coumarin derivative assuage thiram-induced tibial dyschondroplasia by regulating BMP-2 and RUNX-2 expressions in chickens[J].Antioxidants,2019,8(9):330.
[24] MOLINA P,GóRRIZ J L,MOLINA M D S,et al.What is the optimal level of vitamin D in non-dialysis chronic kidney disease population?[J].World J Nephrol,2016,5(5):471-481.
[25] ZHANG Z G,BAI D,JU D H,et al.Therapeutic effect of aqueous extract from ecliptae herbs on bone metabolism of ovariectomized rats[J].Menopause(New York),2013,20(2):232-240.
[26] ELIAS R M, DALBONI M A, COELHO A C E,et al.CKD-MBD:from the pathogenesis to the identification and development of potential novel therapeutic targets[J].Current Osteoporosis Reports,2018,16(6):693-702.
[27] BOVER J, URE?A-TORRES P, ALONSO A M L,et al.Osteoporosis,bone mineral density and CKD-MBD(II):therapeutic implications[J].Nefrología(English Edition),2019,39(3):227-242.
[28] HRUSKA K A,SUGATAN T,AGAPOVA O,et al,The chronic kidney disease-Mineral bone disorder(CKD-MBD):advances in pathophysiology[J].Bone,2017,100(3):80-86.

备注/Memo

备注/Memo:
基金项目:国家重点研发计划项目(2018YFC1704300)
国家自然科学基金项目(81673991,81973876)
上海市重中之重临床医学中心建设项目(2017ZZ01010)
上海市卫计委科研项目(20174Y0192)
教育部创新团队发展计划项目(IRT1270)
科技部重点领域创新团队项目(2015)
*共同第一作者
△通信作者 E-mail:siren17721101@163.com
更新日期/Last Update: 1900-01-01